Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 24, 2016 - Issue 2
Submit an article Journal homepage
1,876
Views
8
CrossRef citations to date
0
Altmetric
Editorial

Drugs, Inflammation, and the Eye

Emmett T. Cunningham JrCalifornia Pacific Medical Center, San Francisco, California, USA, ;The Department of Ophthalmology, Stanford University School of Medicine, Stanford, California, USA, ;The Francis I. Proctor Foundation, UCSF School of Medicine, San Francisco, California, USA, ;West Coast Retina Medical Group, San Francisco, California, USA, Correspondence[email protected]
, MD, PhD, MPH,
Nikolas J. S. LondonRetina Consultants San Diego, La Jolla, California, USA,
, MD,
Ramana MoorthyAssociated Vitreoretinal and Uveitis Consultants, Indiana University School of Medicine, Indianapolis, Indiana, USA,
, MD,
Sunir J. GargMidAtlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania, USA, and
, MD &
Manfred ZierhutCentre for Ophthalmology, University Tuebingen, Tuebingen, Germany
, MD
Pages 125-127 | Published online: 13 Apr 2016

References

  • London NJ, Garg SJ, Moorthy RS, et al. Drug-induced uveitis. J American Academy of Ophthalmology, Focal Points. June, 2015 (Module 2 of 3); Vol. XXXIII, Number 5:1--4
  • Shifera AS, Kopplin L, Lin P, et al. Drug-induced uveitis. Int Ophthalmol Clin. 2015 Spring; 55:47–65
  • London NJ, Garg SJ, Moorthy RS, et al. Drug-induced uveitis. J Ophthalmic Inflamm Infect. 2013;3:43–60
  • Moorthy RS, London NJ, Garg SJ, et al. Drug-induced uveitis. Curr Opin Ophthalmol. 2013;24:589–597
  • Cunningham ET Jr, Pasadhika S, Suhler EB, et al. Drug-induced inflammation in patients on TNFalpha inhibitors. Ocul Immunol Inflamm. 2012;20:2–5
  • Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60
  • Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148
  • Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211
  • Beltz J, Zamir E. Brimonidine induced anterior uveitis. Ocul Immunol Inflamm. 2016;24:128--133
  • Lefebvre DR, Mandeville JT, Yonekawa Y, et al. A case series and review of bisphosphonate-associated orbital inflammation. Ocul Immunol Inflamm. 2016;24:134--139
  • Papavasileiou E, Prasad S, Freitag SK, et al. Ipilimumab-induced ocular and orbital inflammation—A case series and review of the literature. Ocul Immunol Inflamm. 2016;24:140--146
  • Cunningham ET Jr. The expanding spectrum of viral anterior uveitis. Ophthalmology. 2011;118:1903–1904
  • Cunningham ET Jr, Baglivo E. Fuchs heterochromic iridocyclitis—Syndrome, disease, or both? Am J Ophthalmol. 2009;148:479–481
  • Sharma S, Trikha S, Perera SA, et al. Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2015;9:2201–2207
  • Reid IR, Gamble GD, Mesenbrink P, et al. Characterization of and risks for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95:4380–4387
  • Patel DV, Horne A, House M, et al. The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology. 2013;120:773–776
  • Patel DV, Bolland M, Nisa Z, et al. Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. Osteoporos Int. 2015;26:499–503
  • Patel DV, Horne A, Mihov B, et al. The effects of re-challenge in patients with a history of acute anterior uveitis following intravenous zoledronate. Calcif Tissue Int. 2015;97:58–61
  • Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report. Can J Ophthalmol. 2016;51:e4–e6
  • Abu Samra K, Valdes-Navarro M, Lee S, et al. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol. 2015. Dec19:0. DOI: 10.5301/ejo.5000724. [Epub ahead of print]
  • de Velasco G, Bermas B, Choueiri TK. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol. 2016;68:556–557

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.